Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
COMMENTARY
Diabetes Market Regaining Momentum with New Launches; First Oral GLP-1 a Game Changer?
The diabetes drug market is heating up again. Novo Nordisk Pharma’s Rybelsus (semaglutide), the first oral GLP-1 receptor agonist in Japan, was approved on June 29, while a number of insulin combination products and biosimilars have been launched as well.…
To read the full story
Related Article
- Chugai, Sanofi Wind Up License Deal for Apleway; Kowa to Get MA
February 18, 2020
- MSD to Transfer Japan Distribution Rights for DPP-4 Inhibitor Marizev to Kissei
February 4, 2020
- Novo Joins Hands with MSD in Oral Semaglutide Promotion
December 10, 2019
- Sumitomo Dainippon to Solely Promote Novartis Diabetes Meds from January
November 20, 2019
- Taisho, Novartis to Stop Comarketing Lusefi at December-End
October 31, 2019
COMMENTARY
- As US Pushes Global Cost Rebalancing, Can Japan Answer with Drug Prices?
September 7, 2026
- Pharma Faces Wage Challenge in 5% Era as Industry Sustainability at Stake
September 3, 2026
- Beyond Dupixent: Next Wave of COPD Biologics Takes Shape
August 25, 2026
- 9 Drugs Top 100 Billion Yen in FY2025 Japan Sales; Keytruda Retains Crown: Jiho Tally
August 20, 2026
- Signs of Shift in Japan’s Drug Policy, but Cost Pressures Persist
August 3, 2026
Japan has entered a third straight year of wage hikes averaging 5%, but the pharmaceutical industry is struggling to keep…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…